Toxicity by pyruvate in HepG2 cells depleted of glutathione: role of mitochondria.
Several studies have shown that pyruvate can scavenge H(2)O(2) and protect from H(2)O(2)-mediated cell injury. Mitochondria are critical participants in the control of apoptotic and necrotic cell death. Mitochondrial GSH plays an important role in the maintenance of cell functions and viability by metabolism of oxygen free radicals generated by the respiratory chain. Since loss of GSH, especially mitochondrial GSH, is associated with increased production of reactive oxygen species and cell toxicity, the ability of pyruvate to protect against these actions was evaluated. Adding pyruvate to HepG2 cells depleted of GSH by treatment with l-buthionine sulfoximine (BSO) surprisingly caused loss of viability after 24 and 48 h of incubation. Anoxia, treatment with antioxidants, and infection with cytosolic catalase, and interestingly, catalase expressed in the mitochondrial compartment were able to rescue the HepG2 cells from this pyruvate plus BSO injury, suggesting a key role for H(2)O(2), and lipid peroxides as mediators in the cytotoxicity. This toxicity and cell death observed was linked to damage to the mitochondria as evidenced by the increased lipid peroxidation in total homogenate and mitochondrial fraction, loss of mitochondrial membrane potential, and a decrease in protein-sulfhydryl groups. The type of cell death observed under these conditions was a mixture of apoptosis and necrosis. These results suggest that the protective ability of pyruvate against oxidant damage requires a functional GSH pool, especially in the mitochondrial compartment, and that in the absence of GSH, pyruvate increases cell injury by damaging the mitochondria, presumably as a consequence of enhanced electron flow and reactive oxygen production by the respiratory chain.
Marí
Montserrat
M
Department of Biochemistry and Molecular Biology, Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029, USA.
Bai
Jingxiang
J
Cederbaum
Arthur I
AI
D000975:Antioxidants / Q000494:pharmacology; D017209:Apoptosis; D019328:Buthionine Sulfoximine / Q000633:toxicity; D006528:Carcinoma, Hepatocellular; D002374:Catalase / Q000494:pharmacology; D005978:Glutathione / Q000172:deficiency / Q000378:metabolism*; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D008928:Mitochondria / Q000187:drug effects* / Q000378:metabolism; D009336:Necrosis; D010100:Oxygen / Q000378:metabolism; D011773:Pyruvates / Q000633:toxicity*; D013438:Sulfhydryl Compounds / Q000037:antagonists & inhibitors; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism
D000975:Antioxidants; D011773:Pyruvates; D013438:Sulfhydryl Compounds; D019328:Buthionine Sulfoximine; D002374:Catalase; D005978:Glutathione; D010100:Oxygen